Table 2 Change in lipid profiles, AI, mFRS, and IR in patients receiving biologic or biologic-naïve therapy

Total cholesterol, mg/dL

  Baseline

212.3 ± 5.8

195.3 ± 9.8

191.8 ± 5.3

209.6 ± 11.2

  Week 24

212.1 ± 5.6

191.0 ± 7.9

211.5 ± 6.8*

199.5 ± 8.6

HDL-C, mg/dL

  Baseline

73.0 ± 2.7

67.5 ± 4.1

67.7 ± 3.3

70.4 ± 4.4

  Week 24

77.1 ± 3.8

71.7 ± 4.0

72.1 ± 4.0

70.8 ± 5.2

LDL-C, mg/dL

  Baseline

131.3 ± 5.3

118.4 ± 8.9

119.2 ± 5.5

123.4 ± 9.1

  Week 24

127.0 ± 5.6

117.0 ± 7.4

134.3 ± 6.5*

114.2 ± 6.0

Triglyceride, mg/dL

  Baseline

105.6 ± 8.3

129.8 ± 21.1

118.8 ± 9.8

86.9 ± 9.3

  Week 24

105.7 ± 7.1

106.4 ± 12.0

135.5 ± 11.4*

88.9 ± 9.6

Atherogenic index

  Baseline

3.00 ± 0.11

3.05 ± 0.29

2.94 ± 0.12

3.11 ± 0.18

  Week 24

2.91 ± 0.14

2.75 ± 0.16

3.11 ± 0.16

3.01 ± 0.20

Modified FRS

  Baseline

3.52 ± 0.65

4.22 ± 1.44

3.48 ± 0.91

3.43 ± 0.93

  Week 24

3.42 ± 0.72

4.22 ± 1.40

4.04 ± 0.97*

3.25 ± 0.79

Insulin resistance

  Baseline

2.75 ± 0.29

2.90 ± 0.53

2.97 ± 0.38

2.28 ± 0.34

  Week 24

1.76 ± 0.39*

1.71 ± 0.26**

1.99 ± 0.25**

1.77 ± 0.18